The global peripheral neuropathy treatment market provides therapeutic treatments for peripheral nerve damage caused due to various medical conditions such as diabetes, chemotherapy, alcohol consumption and nutritional deficiencies. Peripheral neuropathy commonly affects nerves in the hands and feet which causes symptoms ranging from numbness, tingling, pain to weakness. The main causes of peripheral neuropathy include diabetes, chemotherapy drugs, certain medicines, toxins exposure, HIV/AIDS, kidney failure and autoimmune disorders. Diabetes accounts for over 50% of peripheral neuropathy cases as high blood sugar levels usually damages nerves over time. The increasing prevalence and incidence of diabetes globally has spurred the need for effective peripheral neuropathy treatment options.

The Global peripheral neuropathy treatment market Demand is estimated to be valued at US$ 2146.54 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the peripheral neuropathy treatment market are DMedHOK, Inc., Safecare Technology, Octal IT Solution, McKesson Corporation, LS Retail ehf., Liberty Software, Inc., GlobeMed Group, Datascan, Cerner Corporation, Allscripts Healthcare, LLC, and Epicor Software Corporation, among others.

The rising incidence of diabetes is a major factor fueling the demand for peripheral neuropathy treatments. According to the International Diabetes Federation, around 537 million adults were living with diabetes in 2021 worldwide and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Long-term complications of diabetes such as damage to nerves gradually increases the risk of peripheral neuropathy.

The market is also witnessing increased expansion across global territories driven by growing healthcare investments and expenditure in emerging nations. Moreover, favorable regulations and reimbursement policies have encouraged pharmaceutical companies to further invest in developing novel and advanced treatment therapies.

Market Drivers

The increasing prevalence of diabetes is a key factor driving the peripheral neuropathy treatment market growth. Peripheral neuropathy is a common diabetes complication that occurs in 60-70% of diabetes patients. High blood glucose levels in diabetes can damage nerve fibers over time making them more susceptible to injury and less able to send messages between the body and brain. This eventually leads to symptoms of peripheral neuropathy. As diabetes cases continue to spike worldwide, the demand for timely and effective neuropathy treatment is also expected to surge significantly.

The current geopolitical situation is impacting the growth of the Peripheral Neuropathy Treatment Market in several ways. Strained relations between major economies have disrupted global supply chains and lowered trade volumes. This has reduced the availability of key drugs and medical devices needed for peripheral neuropathy treatment. It has also led to rising costs due to higher transportation and logistical challenges. The conflict between Russia and Ukraine is another factor hindering market expansion. Both countries have a sizable patient population suffering from peripheral neuropathy. However, the ongoing war is severely limiting access to modern treatment options in the region.

To address these headwinds, companies must diversify their manufacturing and supplier networks across different geographies. Having backup plans and alternatives can help mitigate risks from future geopolitical uncertainties or trade restrictions. Investing in R&D of therapeutic approaches that rely less on imported components can provide a competitive edge. Partnerships with local distributors and healthcare providers must also be strengthened to continue serving patients, especially in conflict-affected areas. Overall, a flexible and adaptive long-term strategy is needed to navigate the volatile geopolitical environment and sustain market growth over the forecast period.

In terms of regional concentration, North America currently dominates the peripheral neuropathy treatment market in terms of value. This is due to the rising prevalence of diabetes and other conditions causing neuropathy. Availability of advanced treatment options and higher healthcare spending also contribute to North America's large market share. Europe follows North America owing to increasing research focus on neuropathies by pharmaceutical firms.

The fastest growing regional market for peripheral neuropathy treatment is expected to be Asia Pacific. Rapid economic development and expanding access to healthcare are major factors fueling market growth. Countries like China and India have a huge patient population base with high unmet needs. Growing medical tourism and partnerships between global drug makers and local generics firms will further support the Asia Pacific market's fastest growth over the coming years.

Get more insights on this topic: Peripheral Neuropathy Treatment Market